NCT06904599View on ClinicalTrials.gov

Efficacy of Human Chorionic Gonadotropin in Acute GVHD Treatment

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Acute Graft Versus Host Disease
Interventions
DRUG

Human chorionic gonadotropin (hCG)

2500 IU intramuscular on days 1, 3, and 5 of the protocol. Patients who have at least a partial response by day 7 will receive 3 weekly doses for an additional 4 weeks.

DRUG

Prednisone

Oral prednisone 1 mg/kg/day for 14 days

DRUG

Dexamethasone

IV dexamethasone 0.15 mg/kg/day for 14 days

Trial Locations (1)

64460

RECRUITING

Universidad Autónoma de Nuevo León, Monterrey

All Listed Sponsors
collaborator

Marisa Romero Martínez

UNKNOWN

collaborator

Dr. José Carlos Jaime Perez

UNKNOWN

collaborator

Dr. David Gómez Almaguer

UNKNOWN

collaborator

Dra. Consuelo Mancias Guerra

UNKNOWN

collaborator

Dr. Andrés Gómez de León

UNKNOWN

collaborator

Dra. Olga Graciela Catú Rodríguez

UNKNOWN

collaborator

Dra. Perla Colunga Pedraza

UNKNOWN

collaborator

Dra. Michelle Morcos Sandino

UNKNOWN

lead

Hospital Universitario Dr. Jose E. Gonzalez

OTHER